IntegoTM infusion system: cost effectiveness analysis focusing on dosimetry, sterility and management
| Autor: | Federica Matteucci, Laura Solinas, David Bianchini, Andrea Moretti, Davide Gallegati, Vincenzo D’Errico, Giovanni Paganelli, Caterina Donati, Valentina Turri, Mattia Altini |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Marginal cost
medicine.medical_specialty Cost–benefit analysis Sterility business.industry Cost effectiveness Cost-Benefit Analysis Cost-effectiveness analysis Radiation Exposure Choline Injections Positron-Emission Tomography medicine Dosimetry Radiology Nuclear Medicine and imaging Medical physics Radiation protection business Radiometry Reimbursement |
| Zdroj: | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 63(2) |
| ISSN: | 1827-1936 |
| Popis: | Background Healthcare providers across Europe are facing an ever-growing demand in clinical PET referrals. Currently, it is estimated that the administration of the PET tracer accounts for approximately 40% of the unitary PET procedure reimbursement (uPETr). Although the cost of PET/CT is highly dependent on the radiopharmaceutical cost itself, little is known about the economic impact of the utilized administration method and the repercussions on staff radiation exposure. Our objective was to evaluate the cost-effectiveness of automatic injection/fractionation system Intego™ (Bayer HealthCare, MEDRAD Europe, Netherlands) for istaff radiation exposure reduction and to validate its use with 18F-choline (FCH). Methods In order to validate Intego™ use with FCH we analyzed sterility, radioactivity fractionation accuracy and radiation protection for staff. We analyzed Intego™ impact on examination costs and its impact on organization efficiency. A cost-effectiveness analysis (CEA) was estimated as the incremental cost to reduce staff radiationexposure. Results According to our data, Intego™ ensures both sterility and accuracy of FCH doses' activity, reducing, at the same time, the exposure to radiation either whole body and at the extremities (94% and 75% respectively for the technicians and complete reduction for physicians). Intego™'s variable unit costs are higher than the SA (respectively 1.8% and 0.4% of PET reimbursement), while staff costs are significantly higher with SA (respectively 0.27% and 1.57% of unitary PET reimbursement [uPETr]). In our simulation, based on a 2,450 PET yearly output, the differential costs were slightly higher by using Intego™™ (+ 14%). The incremental cost-effectiveness ratio (ICER) was equal to 1.1, i.e. the healthcare provider pays an additional cost of 0.38% of uPETr to obtain a significant reduction of staff radiation exposure (-4.5 µS). Conclusions Intego™, for its favorable results in terms of cost effectiveness, could be a useful tool in a nuclear medicine department, limiting the staff radiation exposure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|